Based on the information available, the US Food and Drug Administration (FDA) has not issued any recent communication indicating that they have found new risks for Lipitor's liver safety. The most recent information regarding Lipitor and liver safety comes from a 2012 safety announcement by the FDA [1]. In this announcement, the FDA stated that they had updated the labels of Lipitor and other similar statin drugs to include information about the potential for increased blood sugar and cholesterol levels, as well as the risk of liver damage. However, the FDA did not mention any new risks related to Lipitor's liver safety.

It is important to note that Lipitor, like all medications, has potential side effects and risks. The FDA advises that patients should speak with their healthcare provider if they have any concerns about their medications [1]. Additionally, DrugPatentWatch.com, a website that tracks drug patents and pharmaceutical industry news, does not have any recent information regarding new risks for Lipitor's liver safety [2].

In conclusion, based on the available information, there is no evidence to suggest that the FDA has found new risks for Lipitor's liver safety. However, as with any medication, patients should speak with their healthcare provider if they have any concerns about potential side effects or risks.

Sources:
[1] FDA (2012). FDA updates labels of cholesterol-lowering statin drugs to manage risk of liver damage and diabetes. <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-updates-labels-cholesterol-lowering-statin-drugs-manage-risk-liver-damage-and-diabetes>
[2] DrugPatentWatch.com (n.d.). Lipitor. <https://www.drugpatentwatch.com/drugs/lipitor>